title: Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.
abstract: Metacavir (PNA) is a novel synthetic nucleoside analogue for the treatment of hepatitis B virus (HBV). Our recent studies showed that PNA, a prodrug of 2',3'-dideoxyguanosine (ddG), exhibited lower mitochondrial toxicity in long-term cultures of HepG2 cells. In the current study, we examined the long-term effects of PNA on mitochondrial toxicity in Marmota himalayana (Himalayan marmot). Himalayan marmots were treated daily with oral PNA (50 or 100 mg/kg), ziduvidine (AZT) (100 mg/kg), or water (control) for 90 days. PNA treatment did not alter the body weight or plasma lactate acid level. In livers from the animals treated with PNA at 100 mg/kg/day, histopathology showed mild steatosis or small focal liver cell necrosis. Electron microscopy also showed minor proliferation and partial mitochondrial swelling with crista reduction. Measurement of respiratory chain complex enzyme activity and mitochondrial DNA (mtDNA) content revealed no significant differences in skeletal muscle, liver, and kidney tissues between animals treated with PNA and controls. In contrast, in Himalayan marmots treated with AZT we observed delayed toxicity, including lactic acidosis, severe hepatic steatosis, obvious mitochondrial damage, and significant decreases in respiratory chain complex enzyme activity and mtDNA content. This is similar to the delayed toxicity syndrome observed previously in animals and humans. In summary, PNA treatment did not alter mitochondrial enzyme activity or mtDNA content. This suggests that PNA could pose a very low risk for adverse mitochondrion-related effects. However, long-term hepatotoxic effects of PNA were observed, and this indicates a need for continued monitoring of PNA-associated hepatotoxicity in clinical trials.
authors.affiliation: Jiangsu Center for New Drug Screening and National Drug Screening Laboratory, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
authors.forename: Pinghu
authors.initials: P
authors.lastname: Zhang
authors.forename: Luyong
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhenzhou
authors.initials: Z
authors.lastname: Jiang
authors.forename: Yating
authors.initials: Y
authors.lastname: Xiong
authors.forename: Hongkui
authors.initials: H
authors.lastname: Chen
authors.forename: Yuanqing
authors.initials: Y
authors.lastname: Tao
authors.forename: Maozhi
authors.initials: M
authors.lastname: Hu
authors.forename: Zhan
authors.initials: Z
authors.lastname: Li
mesh_terms: D000140:Acidosis, Lactic / Q000139:chemically induced; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004272:DNA, Mitochondrial / Q000235:genetics; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000494:pharmacology; D005234:Fatty Liver / Q000139:chemically induced; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects; D019344:Lactic Acid / Q000097:blood; D008392:Marmota; D008928:Mitochondria / Q000187:drug effects*; D011355:Prodrugs / Q000009:adverse effects / Q000494:pharmacology; D011684:Purine Nucleosides / Q000009:adverse effects / Q000494:pharmacology; D015215:Zidovudine / Q000009:adverse effects / Q000494:pharmacology
chemical_list: C529213:2-amino-9-(2,3-dideoxy-2,3-dihydroarabinofuranosyl)-6-methoxy-9H-purine; D000998:Antiviral Agents; D004272:DNA, Mitochondrial; D015224:Dideoxynucleosides; D011355:Prodrugs; D011684:Purine Nucleosides; D019344:Lactic Acid; D015215:Zidovudine; C050220:2',3'-dideoxyguanosine